CohBar (NASDAQ:CWBR – Get Rating) released its earnings results on Monday. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01), MarketWatch Earnings reports. During the same quarter in the previous year, the firm posted ($0.07) EPS.
Shares of CohBar stock opened at $0.20 on Wednesday. The stock has a market capitalization of $17.40 million, a P/E ratio of -0.95 and a beta of 2.49. CohBar has a 52-week low of $0.18 and a 52-week high of $2.27. The stock’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.36.
Separately, Zacks Investment Research upgraded CohBar from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Friday, April 1st.
CohBar Company Profile (Get Rating)
CohBar, Inc, a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.
- Get a free copy of the StockNews.com research report on CohBar (CWBR)
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
Receive News & Ratings for CohBar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CohBar and related companies with MarketBeat.com's FREE daily email newsletter.